# To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

> **NCT07208591** · PHASE3 · RECRUITING · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 406 (estimated)

## Conditions studied

- Acute Respiratory Distress Syndrome (ARDS)

## Interventions

- **DRUG:** STSA-1002 injection
- **DRUG:** STSA-1002 Injection Placebo

## Key facts

- **NCT ID:** NCT07208591
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-31
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07208591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07208591, "To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07208591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*